AutoGenomics Introduces its CE–Marked INFINITI® Buccal Sample Collection Kit

CARLSBAD, Calif. - Sept. 20, 2016 - PRLog -- AutoGenomics, Inc., a leader in providing automated molecular testing solutions, announced today that it has introduced its CE-Marked INFINITI^® Buccal Sample Collection Kit for the international market.

The INFINITI^® Buccal Sample Collection Kit enables fast and easy collection of DNA from the cells inside an individual's cheek and provides a less invasive alternative to blood collection.  The flocked swab in the INFINITI^® Buccal Sample Collection Kit provides significant sample absorption and requires short and simplified sample collection.  Right after collection, the swab is immersed in the proprietary DNA stabilizing liquid and cells are efficiently washed off the flocked swab.  The DNA remains intact at room temperature and bacterial growth is inhibited, thus providing high quality DNA that is excellent for use with the AutoGenomics' INFINITI® Plus and High Throughput Systems which utilize Polymerase Chain Reaction (PCR) technology.

"With the INFINITI^® Buccal Sample Collection Kit, our customers can confidently utilize buccal samples and forego the need for blood samples for many of their molecular tests," said Fareed Kureshy, President and Chief Executive Officer of AutoGenomics.

AutoGenomics intends to submit data to the US FDA to support a 510(k) notification for the use of the INFINITI^® Buccal Sample Collection Kit in US market.

About AutoGenomics

AutoGenomics Inc., a privately held company based in Carlsbad, CA, developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers.  AutoGenomics' molecular diagnostics proprietary technology platform is in use globally in clinical reference laboratories, contract research organizations (CRO's), specialty clinics and hospital laboratories.  The platform consists of a family of INFINITI^® analyzers including the INFINITI^® PLUS, a prepared sample to answer system, and the INFINITI^® High Throughput System, which has the capability of producing over 6,000 patient results per day.  The platform also includes five US FDA cleared tests and a menu of over 65 genetic tests for potential application in the areas of personalized medicine (pain management, cardiovascular health assessment and mental health therapy), women's health, oncology, infectious diseases and genetic disorders.  With the discovery of genes and their link to various disease states, the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of precision medicine. www.autogenomics.com.